Why Juno Therapeutics Shares Vaulted 46% Higher in August – Motley Fool
|
Why Juno Therapeutics Shares Vaulted 46% Higher in August
Motley Fool … with a historically poor prognosis, too. Together, these developments show chimeric antigen receptor T–cell therapy, or CAR-T, which involves reengineering a patient's T–cells to spot and destroy cancer cells, could be the next big thing in cancer … |
